因编辑、细胞治疗与RNA技术前沿报告行业现状（英）

2025-08生物技术41免费

📄 文件全名: 《因编辑、细胞治疗与RNA技术前沿报告行业现状（英）-41页.pdf》
🎯 适合读者: 战略规划行业研究员
📊 核心数据: the 80 gene therapy trials initiated in Q2, 64% are for oncology indications, the highest proportion
76% were for non-oncology indications. In the RNA therapy pipeline, 38 trials were initiated in Q2, up
from 35 last quarter, of which 74% were for non-oncology indications.
Acquisitions of CGT assets continue to increase quarter by quarter, with a 33% jump in volume,
🏷️ 核心议题: #细胞治疗

📦 本报告属于月份合集

购买后将获得「2025 年 8 月报告合集」 · 共 3951 份报告打包下载链接

点击获取云盘下载链接

报告摘要

Gene, Cell, & RNA Therapy Q2 2025 Quarterly Data Report Key takeaways from Q2 2025

❓ 常见问题

《因编辑、细胞治疗与RNA技术前沿报告行业现状（英）》主要包含哪些内容?

Gene, Cell, & RNA Therapy Q2 2025 Quarterly Data Report Key takeaways from Q2 2025核心数据:the 80 gene therapy trials initiated in Q2, 64% are for oncology indications, the highest proportion;76% were for non-oncology indications. In the RNA therapy pipeline, 38 trials were initiated in Q2, up;from 35 last quarter, of which 74% were for non-oncology indications.。

这份报告覆盖哪一年、篇幅多大?

覆盖 2025 年,全文约 41。

这份报告是免费的吗?如何获取?

本报告免费查阅,登录资料宝后即可在线获取完整内容。

这份报告适合哪些读者?

适合战略规划、行业研究员等读者参考。

报告涉及哪些关键议题?

重点分析了细胞治疗等议题。